Affiliation:
1. JMI Laboratories, North Liberty, Iowa, USA
Abstract
The
in vitro
activities of gepotidacin and comparator agents against 3,560
Escherichia coli
and 344
Staphylococcus saprophyticus
collected from female (81.1%) and male (18.9%) patients with urinary tract infections (UTIs) in a global prospective surveillance program in 2019 to 2020 were determined. Isolates collected from 92 medical centers in 25 countries, including the United States, Europe, Latin America, and Japan, were tested for susceptibility by reference methods in a central monitoring laboratory.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology